GB201022077D0 - Inactivated poliovaccine - Google Patents

Inactivated poliovaccine

Info

Publication number
GB201022077D0
GB201022077D0 GBGB1022077.0A GB201022077A GB201022077D0 GB 201022077 D0 GB201022077 D0 GB 201022077D0 GB 201022077 A GB201022077 A GB 201022077A GB 201022077 D0 GB201022077 D0 GB 201022077D0
Authority
GB
United Kingdom
Prior art keywords
sabin
coding region
base pairs
inactivated poliovaccine
poliovaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1022077.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Priority to GBGB1022077.0A priority Critical patent/GB201022077D0/en
Publication of GB201022077D0 publication Critical patent/GB201022077D0/en
Priority to US13/977,399 priority patent/US9402892B2/en
Priority to PCT/GB2011/001779 priority patent/WO2012090000A1/en
Priority to RU2013135290/10A priority patent/RU2599453C2/ru
Priority to BR112013017014-0A priority patent/BR112013017014B1/pt
Priority to JP2013546763A priority patent/JP5955860B2/ja
Priority to AU2011350995A priority patent/AU2011350995B2/en
Priority to ES11807966.4T priority patent/ES2574178T3/es
Priority to EP11807966.4A priority patent/EP2658571B1/en
Priority to CN201180063532.4A priority patent/CN103391788B/zh
Priority to CA2821859A priority patent/CA2821859C/en
Priority to DK11807966.4T priority patent/DK2658571T3/en
Priority to ZA2013/04415A priority patent/ZA201304415B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32661—Methods of inactivation or attenuation
    • C12N2770/32662—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB1022077.0A 2010-12-29 2010-12-29 Inactivated poliovaccine Ceased GB201022077D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1022077.0A GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine
DK11807966.4T DK2658571T3 (en) 2010-12-29 2011-12-29 Inactivated polio vaccine
AU2011350995A AU2011350995B2 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
PCT/GB2011/001779 WO2012090000A1 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
RU2013135290/10A RU2599453C2 (ru) 2010-12-29 2011-12-29 Инактивированная полиовакцина
BR112013017014-0A BR112013017014B1 (pt) 2010-12-29 2011-12-29 Poliovírus recombinante atenuado, seu uso, vacina e método para a preparação de uma poliovacina inativada
JP2013546763A JP5955860B2 (ja) 2010-12-29 2011-12-29 不活化ポリオワクチン
US13/977,399 US9402892B2 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
ES11807966.4T ES2574178T3 (es) 2010-12-29 2011-12-29 Vacuna inactivada contra la poliomielitis
EP11807966.4A EP2658571B1 (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
CN201180063532.4A CN103391788B (zh) 2010-12-29 2011-12-29 灭活的脊髓灰质炎疫苗
CA2821859A CA2821859C (en) 2010-12-29 2011-12-29 Inactivated poliovaccine
ZA2013/04415A ZA201304415B (en) 2010-12-29 2013-06-14 Inactivated poliovaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1022077.0A GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine

Publications (1)

Publication Number Publication Date
GB201022077D0 true GB201022077D0 (en) 2011-02-02

Family

ID=43599090

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1022077.0A Ceased GB201022077D0 (en) 2010-12-29 2010-12-29 Inactivated poliovaccine

Country Status (13)

Country Link
US (1) US9402892B2 (https=)
EP (1) EP2658571B1 (https=)
JP (1) JP5955860B2 (https=)
CN (1) CN103391788B (https=)
AU (1) AU2011350995B2 (https=)
BR (1) BR112013017014B1 (https=)
CA (1) CA2821859C (https=)
DK (1) DK2658571T3 (https=)
ES (1) ES2574178T3 (https=)
GB (1) GB201022077D0 (https=)
RU (1) RU2599453C2 (https=)
WO (1) WO2012090000A1 (https=)
ZA (1) ZA201304415B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615933D0 (en) 2006-08-10 2006-09-20 Nat Inst Biological Standards & Control Attenuated polioviruses
WO2015193324A1 (en) * 2014-06-17 2015-12-23 Crucell Holland B.V. Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains
GB201700825D0 (en) * 2017-01-17 2017-03-01 Sec Dep For Health Poliovaccine
US12042533B2 (en) * 2018-03-30 2024-07-23 Biological Mimetics, Inc. Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
WO2020075197A1 (en) * 2018-10-10 2020-04-16 Biological E Limited Inactivated poliomyelitis vaccine composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901094D0 (en) 1989-01-18 1989-03-15 Almond Jeffrey W Attenuated viruses
RU2215035C2 (ru) * 1991-12-06 2003-10-27 Уайтхэд институт фор биомедикл рисерч Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
GB9705669D0 (en) 1997-03-19 1997-05-07 British Tech Group Attenuated polioviruses
GB9817082D0 (en) * 1998-08-06 1998-10-07 Btg Int Ltd Attenuated poliovirus vaccine
GB0615933D0 (en) * 2006-08-10 2006-09-20 Nat Inst Biological Standards & Control Attenuated polioviruses

Also Published As

Publication number Publication date
CN103391788A (zh) 2013-11-13
WO2012090000A1 (en) 2012-07-05
ZA201304415B (en) 2014-03-26
EP2658571A1 (en) 2013-11-06
AU2011350995A8 (en) 2013-07-18
US9402892B2 (en) 2016-08-02
CA2821859C (en) 2020-07-07
BR112013017014A2 (pt) 2016-10-25
JP5955860B2 (ja) 2016-07-20
AU2011350995B2 (en) 2016-11-24
EP2658571B1 (en) 2016-03-02
RU2599453C2 (ru) 2016-10-10
RU2013135290A (ru) 2015-02-10
CA2821859A1 (en) 2012-07-05
JP2014502508A (ja) 2014-02-03
AU2011350995A1 (en) 2013-07-04
BR112013017014B1 (pt) 2020-12-15
ES2574178T3 (es) 2016-06-15
DK2658571T3 (en) 2016-05-17
US20130344108A1 (en) 2013-12-26
CN103391788B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
AU2011350995A8 (en) Inactivated poliovaccine
MX373792B (es) Coronavirus.
EA200900288A1 (ru) Вакцина
EP3372685A3 (en) Cell lines for virus production and methods of use
GB2438802A (en) Structure of the hepatitis C virus NS5A protein
SG170751A1 (en) Extractions and methods comprising elder species
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
MX2015003765A (es) Arterivirus.
MX2010005701A (es) Metodo para producir cepa viral vacunal de un virus de la familia reoviridae.
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
MX2018009008A (es) Virus atenuados de bronquitis infecciosa.
MX2021011059A (es) Particulas tipo norovirus con estabilidad mejorada.
WO2008017870A8 (en) Attenuated polio viruses
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
AP2012006258A0 (en) Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
PH12017550047B1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
WO2006078648A3 (en) Rhinovirus vaccines
WO2007044483A3 (en) Attenuated vaccines for non-segmented negative sense rna viruses
WO2011087738A3 (en) 1,4-substituted piperazine derivatives and methods of use thereof
IL320920A (en) Modified Madriaga helices, self-replicating RNA constructs and their uses
GB202313513D0 (en) Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance
MY201019A (en) Composition and Combined Medication Method for Treating Enterovirus Infection

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)